Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$101K Sell
892
-12
-1% -$1.19K 0.01% 468
2026
Q1
$85.1K Buy
904
+175
+24% +$17.5K 0.01% 487
2025
Q4
$72K Hold
729
– – 0.01% 491
2025
Q3
$61.8K Buy
729
+6
+0.8% +$474 0.01% 514
2025
Q2
$49.2K Sell
723
-160
-18% -$10.1K 0.01% 548
2025
Q1
$53.5K Buy
883
+2
+0.2% +$139 0.01% 506
2024
Q4
$60.9K Buy
881
+13
+1% +$926 0.01% 486
2024
Q3
$57.4K Sell
868
-11
-1% -$701 0.01% 483
2024
Q2
$53.3K Buy
879
+594
+208% +$33.6K 0.01% 484
2024
Q1
$16.2K Buy
+285
New +$17.1K ﹤0.01% 679
2023
Q3
– Sell
-165
Closed -$10.3K – 578
2023
Q2
$10.3K Sell
165
-175
-51% -$11.7K ﹤0.01% 716
2023
Q1
$24.6K Sell
340
-10
-3% -$782 0.01% 554
2022
Q4
$28.1K Buy
350
+10
+3% +$765 0.01% 506
2022
Q3
$23K Hold
340
– – 0.01% 501
2022
Q2
$26K Hold
340
– – 0.01% 491
2022
Q1
$27K Buy
340
+35
+11% +$2.55K 0.01% 507
2021
Q4
$22K Buy
+305
New +$20.6K 0.01% 508
2021
Q3
– Sell
-205
Closed -$17K – 596
2021
Q2
$17K Buy
205
+100
+95% +$8.34K ﹤0.01% 563
2021
Q1
$9K Buy
+105
New +$8.96K ﹤0.01% 538

Other funds holding INCY

CVA Family Office's INCY Position: Q2 2026 in Review

CVA Family Office reduced its Incyte (INCY) stake by 1.3% in Q2 2026, selling an estimated $1.19K and leaving 892 shares worth $101K. The position accounts for 0.01% of the portfolio, ranked #468.

CVA Family Office first reported a position in INCY in Q1 2021 and has held it in 19 quarters since. 861 funds tracked by Wall St. Rank hold INCY as of Q2 2026.

  • CVA Family Office held 892 shares of Incyte worth $101K as of Q2 2026.
  • CVA Family Office sold 12 Incyte shares in Q2 2026, an estimated $1.19K.
  • Incyte made up 0.01% of CVA Family Office's portfolio in Q2 2026, its #468 holding.
  • CVA Family Office first reported a position in Incyte in Q1 2021 and has held it in 19 quarters since.
  • 861 funds tracked by Wall St. Rank held Incyte as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.